Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.

PHASE3CompletedINTERVENTIONAL
Enrollment

1,099

Participants

Timeline

Start Date

November 15, 2010

Primary Completion Date

May 16, 2013

Study Completion Date

February 29, 2016

Conditions
Prostate Cancer
Interventions
DRUG

Orteronel

Orteronel tablets

DRUG

Prednisone

Prednisone tablets

DRUG

Orteronel Placebo

Orteronel placebo-matching tablets

Trial Locations (78)

5011

Woodville South

12208

Albany

13057

East Syracuse

14623

Rochester

15212

Pittsburgh

17604

Lancaster

21157

Westminster

23606

Newport News

27607

Raleigh

29605

Greenville

33916

Fort Myers

34952

Port Saint Lucie

37203

Nashville

37404

Chattanooga

45230

Cincinnati

46219

Indianapolis

47130

Jeffersonville

48201

Detroit

65109

Jefferson City

70112

New Orleans

72903

Fort Smith

75231

Dallas

75246

Dallas

75702

Tyler

76022

Bedford

77598

Webster

79106

Amarillo

79761

Odessa

89169

Las Vegas

90025

Los Angeles

92120

San Diego

92501

Riverside

92708

Fountain Valley

94805

Villejuif

97062

Tualatin

99336

Kennewick

99508

Anchorage

07601

Hackensack

Unknown

Salt Lake City

Redcliffe

Hobart

Malvere

Wodonga

Brussels

Kortijk

Liège

Namur

Edmonton

Moncton

Newmarket

Montreal

Hradec Dralove

Kromertz

Modřice

Prague

Zlín

Tallinn

Oulu

Tampere

La Roche-sur-Yon

Le Mans

Lyon

Marseille

Paris

Pátrai

Miskolc

Osztaly

Novara

Rome

Eindhoven

Bielsko-Biala

Goczałkowice Zdrój

Wroclaw

Seville

V1Y2H4

Kelowna

L6T4S5

Brampton

J4V2H3

Greenfield Park

H9R4S3

Pointe-Claire

All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY